Erasca Q1 net loss $35.0M ($0.23/shr); cash $297.7M; naporafenib data shows 13-14 mo median OS

Erasca, Inc.

2024-Q1 EPS reported -$0.23

Net loss $35.0M vs $33.2M YoY; EPS $(0.23) vs $(0.22).
Cash, equivalents & marketable securities $297.7M as of March 31, 2024.
Pooled analysis of naporafenib + trametinib shows median OS 13.0-14.1 months in NRASm melanoma.
Closed oversubscribed $45M private placement in April 2024, extending cash runway into H2 2026.
Upcoming milestones: Phase 3 SEACRAFT-2 initiation Q2 2024; multiple data readouts in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Erasca, Inc. reported the fiscal quarter ended March 31, 2024 results: net income $35.0 million, EPS $(0.23) per basic and diluted share.

Period: the fiscal quarter ended March 31, 2024
Net income: $35.0 million
EPS: $(0.23) per basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $35.0 million, or $(0.23) per basic and diluted share, for the quarter ended March 31, 2024

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.